Skip to main content

Advertisement

Table 2 Summary of clinical characteristics of the MTH and control group patients

From: Cardiac arrest survivors treated with or without mild therapeutic hypothermia: performance status and quality of life assessment

  MTH (n = 16) Control group (n = 15) p-value (p)
Age (years+/− SE) 55.56 ± 2.8 59.4 ± 2.9 0.358
Sex 11 males 11 males 0.779
VF/VT 16/16 13/15 0.131
Asystole 0/16 1/15 0.294
Hypertension 13/16 7/15 0.044
Diabetes 4/16 3/15 0.739
Prior myocardial infarction 2/16 3/16 0.570
Peripheral atherosclerosis 2/16 0/16 0.157
Heart failure 7/16 1/16 0.018
Coronary heart disease 4/16 2/15 0.411
CABG 1/16 0/15 0.325
AF 3/16 1/16 0.316
Renal failure 2/16 1/16 0.583
Prior stroke 1/16 0/15 0.325
Hyperthyroidism 0/16 1/15 0.294
Hypothyroidism 0/16 1/16 0.294
Smoking 9/16 6/16 0.366
COPD/asthma 1/16 1/16 0.962
Dyslipideamia 9/16 6/15 0.366
Final diagnosis    
STEMI 7/16 9/15 0.366
NSTEMI 2/16 3/15 0.570
Cardiac shock 2/16 4/16 0.318
Heart failure 2/16 3/16 0.570
Myocarditis 2/16 1/16 0.583
  1. AF- atrial fibrillation, CABG – coronary artery by-pass grafting, COPD – chronic obstructive pulmonary disease, MTH - mild therapeutic hypothermia, NSTEMI – non-ST elevation myocardial infarction, STEMI – ST-elevation myocardial infarction VF - ventricular fibrillation, VT - ventricular tachycardia. p<0,05 is considered as significant.